An orthotopic prostate cancer model for new treatment development using syngeneic or patient‐derived tumors

Documenti analoghi

• Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer
  di: Catherine H. Marshall, et al.
  Pubblicazione: (2024)
• Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy
  di: Fabio Matrone, et al.
  Pubblicazione: (2024)
• Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
  di: Thomas Büttner, et al.
  Pubblicazione: (2024)
• Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata
  di: Kamil Malshy, et al.
  Pubblicazione: (2024)
• Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix
  di: Shuhei Kamada, et al.
  Pubblicazione: (2024)